In gram-positive bacteria, glycopeptides inhibit the last steps of peptidoglycan synthesis by binding to the C-terminal Dalanyl-D-alanine (D-Ala-D-Ala) dipeptide of peptidoglycan precursors, preventing their incorporation into the cell wall (22) . Five types of acquired glycopeptide resistance, mediated by VanA, -B, -D, -E, and -G, and one type of intrinsic resistance, mediated by VanC, have been described for enterococci. Resistance to glycopeptides is due to production of modified peptidoglycan precursors, ending in D-alanyl-D-lactate (D-Ala-D-Lac) for VanA, VanB, and VanD or in D-alanyl-D-serine (D-Ala-D-Ser) for VanC, VanE, and VanG, which exhibit reduced affinity for vancomycin (7) . VanE-type resistance to low levels of vancomycin in Enterococcus faecalis BM4405 (13) is due to acquisition in the chromosome of the vanE operon, which includes five genes (2) . The vanE gene encodes a ligase that synthesizes the dipeptide D-Ala-D-Ser; vanXY E encodes a bifunctional D,D-peptidase that possesses D,D-dipeptidase and D,D-carboxypeptidase activities, allowing hydrolysis of precursors ending in D-Ala; and vanT E encodes a serine racemase that provides D-Ser for the resistance pathway. In addition to these three genes, which are sufficient to confer vancomycin resistance, two genes, vanR E and vanS E , encode a two-component regulatory system that is implicated in the regulation of expression of the resistance genes (2, 8) . The five genes are cotranscribed from a P E promoter located upstream from vanE (2) . Although the VanS E sensor is likely to be inactive due to the presence of a stop codon in the 5Ј portion of the gene, expression of vancomycin resistance is inducible in BM4405, suggesting cross talk with another two-component system (2) .
In bacteria, DNA supercoiling is essentially controlled by two enzymes: DNA gyrase and topoisomerase IV. Whereas the first enzyme increases supercoiling in an energy-dependent reaction, the second, in the presence of ATP and Mg 2ϩ , removes supercoiling and relaxes DNA (10) . DNA gyrase is an A 2 B 2 complex in which the A subunit is composed of an Nterminal domain involved in DNA breakage and reunion and a C-terminal domain involved in DNA-protein interactions and the B subunit consists of an N-terminal domain containing ATPase activity and a C-terminal domain implicated in interactions with the A protein and DNA (18, 24) . Coumermycin and novobiocin, which belong to the coumarin family, specifically inhibit DNA gyrase activity (14) . The coumarins block the introduction of supercoils into relaxed DNA and relax supercoiled chromosomal DNA by inhibiting the ATPase activity of DNA gyrase (14) . Consequently, DNA replication and cell growth are stopped. Intercalating agents that remove negative supercoils and subinhibitory doses of novobiocin can cause plasmid "curing," that is, a preferential loss of extrachromosomal DNA (19, 26) . The N-terminal domain of GyrB consists of a C-terminal and an N-terminal subdomain (24 kDa), the latter containing the coumarin-binding site (17, 29) .
Prior to the demonstration that the vanE operon was chromosomally located in E. faecalis BM4405 (2), the strain was subjected to plasmid curing by novobiocin in order to determine the genetic support of this acquired operon. Because susceptible derivatives were repeatedly recovered at high frequencies, the aim of this work was to characterize one of these variants.
MATERIALS AND METHODS
Strains, plasmids, and growth conditions. The bacterial strains and plasmids used in this study are described in Table 1 . E. faecalis BM4405 is resistant to low levels of vancomycin (MIC, 16 g/ml) (13) . E. faecalis BM4405-1, obtained after growth in the presence of 12.5 g of novobiocin/ml, was susceptible to vancomycin (MIC, 2 g/ml). E. faecalis JH2-2, used in electrotransformation experiments, is susceptible to glycopeptides and resistant to fusidic acid and rifampin (16) . Escherichia coli Top10 (Invitrogen, Groningen, The Netherlands) was used as the host in cloning experiments. Strains were cultured in brain heart infusion (BHI) broth or agar (Difco Laboratories, Detroit, Mich.) at 37°C. Susceptibility to glycopeptides was determined by Etest as described by the manufacturer (AB Biodisk, Solna, Sweden). The MIC of novobiocin was determined by the method of Steers et al. (25) with 10 5 CFU per spot on BHI agar after 24 h of incubation at 37°C. Susceptibility to novobiocin was also tested by the disk diffusion method on BHI agar.
Plasmid-curing experiments. Dilutions of an E. faecalis BM4405 culture in BHI broth were flooded onto tryptic soy agar (TSA) containing 12.5 g of novobiocin/ml, and the plates were incubated overnight at 37°C. Colonies were screened for vancomycin susceptibility by replica plating on TSA without and with vancomycin (4 g/ml).
Plasmid and strain construction. (i) Plasmid pAT669.
A fragment of BM4405-1 total DNA encompassing the vanE, vanXY E , and vanT E genes and 600 bp upstream from vanE was amplified by using primers E65 and TE6 (Table 2) , containing a SacI and an XbaI site, respectively. The PCR product was digested with SacI and XbaI and cloned into pAT29 (27) . DNA from recombinant plasmid pAT669 (see Fig. 2C ) was introduced into E. faecalis JH2-2 by electrotransformation, and transformants were selected with spectinomycin (60 g/ml).
(ii) Plasmid pAT670. Based on the sequence of the gene for the B subunit of DNA gyrase (GenBank accession number AB059405), the gyrB gene from BM4405 with its ribosome binding site was amplified by PCR with total DNA as a template and oligodeoxynucleotides gyrB6 and gyrB8 (Table 2) , containing a SacI and an XbaI site, respectively. The amplification product was digested with SacI and XbaI, and the insert was ligated in pAT29, yielding plasmid pAT670. The recombinant plasmid was introduced into E. faecalis BM4405-1 by electrotransformation, with selection on spectinomycin (200 g/ml).
Pulsed-field gel electrophoresis. Genomic DNA embedded in agarose plugs was digested with SmaI overnight at 25°C. Fragments were separated on a 0.8% agarose gel with a CHEF (contour-clamped homogenous electric field)-DRIII system (Bio-Rad Laboratories, Hercules, Calif.) under the following conditions: total migration, 24 h; initial pulse, 60 s; final pulse, 120 s; voltage, 6 V/cm; included angle, 120°; temperature, 14°C. DNA was transferred to Hybond N ϩ membranes (Amersham Pharmacia Biotech, Freiburg, Germany) and fixed under UV illumination. Plasmid pAT663 DNA (vanEЈ) (13) PCR and DNA sequencing. The promoter region and the vanE gene cluster (see Fig. 2A ) were amplified by using BM4405-1 DNA as a template and primer pairs specific for the vanE operon as described elsewhere (2) . The gyrB genes of BM4405 and BM4405-1 were amplified by using primer pair gyrB6-gyrB8 (Table  2) . DNA amplification was carried out in a GeneAmp PCR system 2400 thermal cycler (Perkin-Elmer Cetus, Norwalk, Conn.). The PCR products were ligated into pCR2.1 and transformed into E. coli Top10 (Invitrogen). Plasmid DNA was extracted with the commercial Wizard Plus Minipreps DNA purification system (Promega, Madison, Wis.) and labeled with a Dye-Labeled ddNTP Terminator Cycle Sequencing kit (Beckman, Fullerton. Calif.), and the samples were sequenced and analyzed with a CEQ 2000 automated sequencer (Beckman).
Analysis of peptidoglycan precursors. Peptidoglycan precursors were extracted and analyzed as described elsewhere (20) . Strains were grown in BHI broth overnight at 37°C in the absence or in the presence of vancomycin (1 g/ml for BM4405-1 and 4 g/ml for JH2-2/pAT669) with gentle agitation to an optical density at 600 nm (OD 600 ) of 1.0 (mid-exponential phase). Ramoplanin was added to a concentration of 3 g/ml, and incubation was continued for 15 min. Bacteria were harvested, and the cytoplasmic precursors were extracted with 8% trichloroacetic acid (15 min at 4°C), desalted, and analyzed by high-performance liquid chromatography. Results were expressed as the percentages of total late peptidoglycan precursors represented by UDP-
) that were determined from the integrated peak areas.
D,D-Dipeptidase, D,D-carboxypeptidase, and serine racemase activities. Enzymatic activities were assayed in BM4405-1 as described previously (5) . Bacteria grown in BHI broth overnight at 37°C in the absence or presence (1 g/ml) of vancomycin were lysed by treatment with lysozyme (2 g/ml) at 37°C, followed by sonication, and the membrane fraction was pelleted (at 100,000 ϫ g for 45 min). Activities were measured in the supernatant (S100) and in the resuspended pellet (C100) fraction. (20) . Specific activities were defined as the number of nanomoles of product formed at 37°C per minute per milligram of protein contained in the extracts.
RNA techniques. (i) Extraction of total RNA. Total RNA was extracted with the commercially available TOTALLY RNA kit (Ambion, Austin, Tex.) as follows. E. faecalis BM4405-1 was grown to an OD 600 of 0.7. Cells were harvested by centrifugation, resuspended in TE (Tris-HCl, 10 mM; EDTA, 1 mM), and incubated in the presence of lysozyme (1 mg/ml) for 5 min at room temperature. After centrifugation (for 5 min at 15,000 ϫ g), supernatants were extracted in a first step with a mixture containing phenol, chloroform, and isoamyl acohol, followed by a second step with a mixture composed of sodium acetate, acid phenol, and chloroform. Total RNA was precipitated by addition of 1 ml of isopropanol, and the RNA pellets were resuspended in water-diethyl pyrocarbonate plus EDTA. RNA quality was assessed by agarose gel electrophoresis. RNA concentrations were determined by measuring the absorbance at 260 nm.
(ii) Northern blot analysis. Northern blot experiments were performed as described previously (2) . Fragments obtained by PCR using total DNA from BM4405 as a template and primers E37-E38 (vanE), XYE1-XYE2 (vanXY E ), E9-E15 (vanT E ), R2-R6 (vanR E ), and S1-E41 (vanS E ) (2) were labeled with [␣-32 P]dCTP (3,000 Ci/mmol; Amersham Pharmacia Biotech) by using the Megaprime DNA labeling system (Amersham Pharmacia Biotech). Hybridization and washes were performed as described previously (2) . The sizes of the transcripts were determined by using RNA molecular weight marker I (Boehringer, Mannheim, Germany).
(iii) RT-PCR experiments. Total-RNA samples were prepared as described previously (2) . Reverse transcription (RT) was carried out as described previously (2) using 50 pmol of primer vanE2 (5Ј-GTCGATTCTCGCTAATCC). The DNA products were amplified by PCR in an 80-l reaction volume containing the previous 20-l samples of the RT product, 50 pmol each of primers vanE1 (5Ј-TGTGGTATCGGAGCTGCAG) and vanE2, 1ϫ enzyme buffer (QBIOgene, Montreal, Canada), and 2 U of Taq DNA polymerase (QBIOgene). PCR was performed with the following thermal cycling profile: 3 min at 94°C; 18 cycles of amplification consisting of 1 min at 94°C, 1 min at 52°C, and 1 min at 72°C; and a final extension for 7 min at 72°C. RT-PCR products were loaded onto a 1.2% agarose gel and quantified by using Quantity One software (Bio-Rad).
(iv) Primer extension analysis. The putative transcriptional start site for the vanE operon of BM4405 grown in the presence of novobiocin alone (4 g/ml) or of novobiocin and vancomycin (each at 4 g/ml) was located by primer extension using the synthetic oligodeoxynucleotide PE1 (5Ј-CCAATGACCTTCTTCGGT GATCC) as described elsewhere (2) .
RESULTS AND DISCUSSION
Characterization of strain BM4405-1. The E. faecalis VanEtype clinical isolate BM4405 is resistant to 16 g of vancomycin/ml (13) . After growth of the strain in the presence of novobiocin (12.5 g/ml), 7 to 12% of the surviving cells were susceptible to vancomycin (MIC, Յ2 g/ml), and one derivative, BM4405-1, was selected for further studies (Table 1) . Strains BM4405 and BM4405-1 were compared by pulsed-field gel electrophoresis (Fig. 1) . Their SmaI patterns were indistinguishable, and the same-size fragment (ca. 600 kb) from both strains hybridized with a vanE-specific probe (Fig. 1) .
By disk diffusion, BM4405-1 exhibited a reproducibly slightly reduced susceptibility to novobiocin (inhibition zone diameter, 13 mm) relative to that of BM4405 (inhibition zone diameter, 15 mm). In addition, the growth of BM4405 was slower than that of BM4405-1 in the presence of noviobiocin (12 g/ml) in the culture medium. However, this did not translate into a difference in the novobiocin MIC (16 g/ml) as determined by agar dilution using an arithmetic progression.
The organization of the vanE operon in BM4405-1 was determined by PCR mapping with primer pairs specific for every gene of the operon in BM4405 ( Fig. 2B; Table 2 ). Amplified fragments of the expected sizes were obtained, indicating that all the genes were present in BM4405-1 and were in the same order as in strain BM4405 (2) . Determination of the sequence of the operon detected a silent mutation in vanXY E (T1376A) and two mutations leading to amino acid substitutions. The first, in vanE (G597A), resulted in the replacement of aspartate by asparagine (D200N). The second mutation, in the 3Ј-terminal end of the vanR E gene, resulted in the replacement of the terminal tyrosine at position 225 by phenylalanine To analyze the cytoplasmic peptidoglycan precursors, strain BM4405-1, grown in the absence or presence of a subinhibitory concentration of vancomycin (1 g/ml), was incubated in the presence of ramoplanin to inhibit cell wall synthesis immediately after synthesis of the precursors (20) . The results obtained indicated that UDP-MurNAc-pentapeptide was the only late precursor synthesized by noninduced or induced BM4405-1 (Table 3) , as in E. faecalis BM4405 grown in the absence of vancomycin (13) . (2-4, 12). Although high vancomycin-inducible serine racemase activity is produced by BM4405 (13), no VanT activity was detected in membrane extracts from strain BM4405-1, even after growth with a subinhibitory concentration (1 g/ml) of vancomycin. Taken together, these results confirm that the vanE operon is not expressed in BM4405-1.
Functional analysis of the vanE operon of BM4405-1. Plasmid pAT667, with a 4.4-kb insert that includes the vanEXY E T E genes of BM4405 together with 600 bp upstream from vanE, confers inducible vancomycin resistance on E. faecalis JH2-2 (2). To test if the mutation in the vanE gene of BM4405-1 was responsible for the susceptibility of the host, the three resistance genes and 600 bp upstream from vanE were cloned into pAT29, yielding plasmid pAT669 (600 bp, vanEXY E T E ) ( Table  1) , which was introduced into E. faecalis JH2-2 by electrotransformation. The vancomycin MIC for the transformant (8 g/ ml) differed significantly from that for JH2-2 (2 g/ml) ( Table  3 ). The nature of the peptidoglycan precursors of JH2-2/ pAT669 was determined after growth in the absence or presence of vancomycin (4 g/ml). In the absence of vancomycin, UDP-MurNAc-pentapeptide[D-Ala] was mainly synthesized, whereas in the presence of vancomycin, UDP-MurNAc-pentapeptide[D-Ser] was the main precursor produced (Table 3) . Susceptibility to teicoplanin remained unchanged even after induction with vancomycin. These results are similar to those obtained with strain JH2-2/pAT667 (2). Since the vanEXY E T E genes of BM4405-1 conferred inducible vancomycin resistance when introduced into a susceptible E. faecalis strain, the mutation in the vanE gene of BM4405-1 did not account for significant loss of vancomycin resistance in that strain.
Transcriptional analysis of the vanE operon. The start codons of the vanXY E and vanT E genes overlap the termination codons of vanE and vanXY E , respectively, suggesting that the three genes are cotranscribed (2) . In E. faecalis BM4405, a 
b MIC after induction with 4 g of vancomycin/ml. c ND, not determined. d MIC after induction with 1 g of vancomycin/ml.
single transcript of ca. 5,800 bases hybridizes with all the genes in the operon, including vanR E and vanS E (2) . Total RNA from BM4405-1 was analyzed by Northern hybridization with probes internal to every gene in the operon (2), but no transcript was detected (Fig. 3) . No transcripts were detected after induction (vancomycin, 1 g/ml) of BM4405-1 (data not shown).
Primer extension was performed to locate the putative transcriptional start site when BM4405 was grown in the absence or presence of novobiocin alone (4 g/ml) or novobiocin plus vancomycin (4 g/ml each) (Fig. 4) . By using primer PE1, complementary to the 5Ј end of the vanE gene, the transcriptional start site was located, under all growth conditions, 291 bp upstream from the ATG of the vanE gene (Fig. 4) , as determined previously for that strain (2) . This observation suggests that novobiocin did not directly affect the transcriptional start of the vanE operon.
Quantitative RT-PCR was used to determine the level of expression of the vanE operon in BM4405 and BM4405-1 cultivated under various conditions. The strains were grown without antibiotic until an OD 600 of 0.2 was reached. The cultures were then divided in two subcultures called A and B.
Vancomycin (4 g/ml for BM4405 and 1 g/ml for BM4405-1) was added to subculture B, and both cultures were incubated to an OD 600 of 0.7. Subcultures A and B were then divided again into subcultures A1 and A2 and subcultures B1 and B2. Novobiocin (4 g/ml) was added to subcultures A2 and B2. All four cultures were incubated for 1 h, and samples were taken for RT-PCR. Quantification of the amplification products indicated that the levels of expression of the vanE gene in BM4405 were similar in subcultures A1 and A2 and also in subcultures B1 and B2 (data not shown), indicating that novobiocin had no influence on the level of expression of the vanE operon. Further addition of vancomycin to subculture B resulted, as expected, in an increase (of ca. 30%) in vanE expression in subcultures B1 and B2 relative to that in subcultures A1 and A2 (data not shown). These results confirm that (i) novobiocin did not interfere directly with the expression of the vanE operon and (ii) vancomycin induced the expression of the vanE operon, even in the presence of novobiocin.
No RT-PCR products were obtained with BM4405-1, even after induction with a subinhibitory concentration of vancomycin (1 g/ml), confirming that the vanE operon was not expressed in the susceptible strain. Analysis of the gyrB gene. We tested the possibility that the gyrB gene in BM4405-1 had suffered mutations that could be responsible for loss of expression of the vanE operon. The sequences of the amplification products obtained by using E. faecalis gyrB-specific primers (Table 2 ) and total DNA from BM4405 and BM4405-1 as templates were determined. Mutation A1009C was found in the gyrB gene of BM4405-1, leading to replacement of the lysine at position 337 by tyrosine (K337Y). Lysine 337 is known to be involved in ATP binding to the GyrB subunit (15) . The gyrB gene of the parental strain, BM4405, was amplified by PCR and cloned into pAT29, and the recombinant plasmid, pAT670 (Table 3) , was introduced by electrotransformation into BM4405-1. Transformant BM4405-1/pAT670 was resistant to vancomycin (MIC, 8 g/ ml), indicating that lack of expression of the vanE operon of the host was, at least in part, associated with a defect in DNA gyrase activity due to the mutation in the gyrB gene. This result was confirmed by analysis of the peptidoglycan precursors from BM4405-1/pAT670 performed after growth without or with (4 g/ml) vancomycin. In the absence of vancomycin, UDP-MurNAc-pentapeptide[Ala] (55%), UDP-MurNAc-pentapeptide[Ser] (35%), and UDP-MurNAc-tetrapeptide (10%) were synthesized, whereas in the presence of vancomycin, UDP-MurNAc-pentapeptide [Ser] represented 70% of the peptidoglycan precursors (Table 3) . Determination of the nucleotide sequences of the gyrB genes of five other vancomycinsusceptible BM4405 derivatives obtained independently after treatment with novobiocin revealed a mutation in each of them. Four of these mutations led to an amino acid substitution in the N-terminal subdomain of GyrB (E27Q, M35T, D181G, and G345T), and one led to an amino acid substitution in the C-terminal subdomain (R404H). The consequences of these mutations for the activity of GyrB remain unknown, since they have not been reported previously.
Effects of novobiocin on three other VanE-type E. faecalis strains. Three distinct VanE-type E. faecalis strains (vancomycin MICs, 6 to 32 g/ml) (1) were subjected to novobiocin treatment. No derivatives susceptible to vancomycin were obtained in two independent experiments. It seems, therefore, that the effect of novobiocin on expression of the vanE operon is strain dependent. Transcription initiation at numerous bacterial promoters is strongly dependent on supercoiling of the DNA template (9, 21, 28) . Primer extension was performed to locate the putative transcriptional start site of the vanE operon in these strains (1). The putative P E promoter, located upstream of vanE, was identical in the three strains but differed from that in BM4405. The ϩ1 transcriptional start site was located 25 and 291 bp upstream from the start codon in the three strains and in BM4405, respectively (1, 2) . Promoters whose expression depends on a transcriptional activator do not possess a typical Ϫ35 region (11) . Thus, the spacing between the Ϫ35 and Ϫ10 hexamers, which is crucial for promoter activity (28), could not be determined. The lack of a novobiocin effect on the expression of the vanE operon in the three strains could be due to the fact that their P E promoter differs from that of BM4405. In two of these strains expression of the vanE operon was inducible, whereas it was constitutive in the isolate that had a mutation in the vanS E gene (1) . Taken together, these results are consistent with the previous proposal (2) that another two-component regulatory system is responsible for expression of the vanE operon in BM4405 by cross talk.
In conclusion, we have shown that novobiocin treatment of the VanE-type strain BM4405 is indirectly responsible for inactivation of the vanE operon. Mutation of a critical residue (K337Y) in GyrB involved in ATP hydrolysis is likely to be responsible for altered expression of the vanE gene cluster. It appears, therefore, that the level of DNA supercoiling modulates the expression of the vanE operon at the transcriptional level. We have previously proposed that, since the VanS E sensor of BM4405 is not functional, inducible expression of the vanE operon is likely to be due to cross talk with another two-component regulatory system of the cell (2). Whether alteration of DNA supercoiling directly affects the P E promoter or the activity of the putative other two-component system remains to be determined.
